Adjuvant pembrolizumab‐related hyperprogression in stage III melanoma

Adjuvant pembrolizumab‐related hyperprogression in stage III melanoma

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal der Deutschen Dermatologischen Gesellschaft 2021-09, Vol.19 (9), p.1341-1345
Hauptverfasser: Ammann, Nadine L., Geidel, Glenn, Schneider, Stefan W., Gebhardt, Christoffer
Format: Artikel
Sprache:eng
Schlagworte:
Immunotherapy
Melanoma
Monoclonal antibodies
Pembrolizumab
Targeted cancer therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1345
container_issue 9
container_start_page 1341
container_title Journal der Deutschen Dermatologischen Gesellschaft
container_volume 19
creator Ammann, Nadine L.
Geidel, Glenn
Schneider, Stefan W.
Gebhardt, Christoffer
description
doi_str_mv 10.1111/ddg.14535
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2551210221</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2551210221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3255-cb891aad01e03a0a22b0d7d1bc88ce71dcb8125869abac3aab730c99aa867d0b3</originalsourceid><addsrcrecordid>eNp10LtOwzAUBmALgUQpDLxBJBYY0h4nTW2PVQslUiUWmK3jS0uq3LAbUJl4BJ6RJ8EQxICEF3v4fM6vn5BzCiMaztiYzYhOsjQ7IAM6pRBDytnh75uJY3Li_RYgyTjAgCxnZts9Y72LWlsp15TFa1eh-nh7d7bEnTXR4761rnXNxlnvi6aOijryO9zYKM_zqAqqbio8JUdrLL09-7mH5OHm-n5-G6_ulvl8top1mmRZrBUXFNEAtZAiYJIoMMxQpTnXllETAA3RpgIV6hRRsRS0EIh8ygyodEgu-7kh0VNn_U5Whde2DCls03kZltCEQpLQQC_-0G3TuTqkC4oJwdmEi6CueqVd472za9m6okK3lxTkV6UyVCq_Kw123NuXorT7_6FcLJb9j0-Zfnjt</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2579987489</pqid></control><display><type>article</type><title>Adjuvant pembrolizumab‐related hyperprogression in stage III melanoma</title><source>Wiley Online Library - AutoHoldings Journals</source><creator>Ammann, Nadine L. ; Geidel, Glenn ; Schneider, Stefan W. ; Gebhardt, Christoffer</creator><creatorcontrib>Ammann, Nadine L. ; Geidel, Glenn ; Schneider, Stefan W. ; Gebhardt, Christoffer</creatorcontrib><identifier>ISSN: 1610-0379</identifier><identifier>EISSN: 1610-0387</identifier><identifier>DOI: 10.1111/ddg.14535</identifier><language>eng</language><publisher>Berlin: Wiley Subscription Services, Inc</publisher><subject>Immunotherapy ; Melanoma ; Monoclonal antibodies ; Pembrolizumab ; Targeted cancer therapy</subject><ispartof>Journal der Deutschen Dermatologischen Gesellschaft, 2021-09, Vol.19 (9), p.1341-1345</ispartof><rights>2021 Deutsche Dermatologische Gesellschaft (DDG). Published by John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fddg.14535$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fddg.14535$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>Ammann, Nadine L.</creatorcontrib><creatorcontrib>Geidel, Glenn</creatorcontrib><creatorcontrib>Schneider, Stefan W.</creatorcontrib><creatorcontrib>Gebhardt, Christoffer</creatorcontrib><title>Adjuvant pembrolizumab‐related hyperprogression in stage III melanoma</title><title>Journal der Deutschen Dermatologischen Gesellschaft</title><subject>Immunotherapy</subject><subject>Melanoma</subject><subject>Monoclonal antibodies</subject><subject>Pembrolizumab</subject><subject>Targeted cancer therapy</subject><issn>1610-0379</issn><issn>1610-0387</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp10LtOwzAUBmALgUQpDLxBJBYY0h4nTW2PVQslUiUWmK3jS0uq3LAbUJl4BJ6RJ8EQxICEF3v4fM6vn5BzCiMaztiYzYhOsjQ7IAM6pRBDytnh75uJY3Li_RYgyTjAgCxnZts9Y72LWlsp15TFa1eh-nh7d7bEnTXR4761rnXNxlnvi6aOijryO9zYKM_zqAqqbio8JUdrLL09-7mH5OHm-n5-G6_ulvl8top1mmRZrBUXFNEAtZAiYJIoMMxQpTnXllETAA3RpgIV6hRRsRS0EIh8ygyodEgu-7kh0VNn_U5Whde2DCls03kZltCEQpLQQC_-0G3TuTqkC4oJwdmEi6CueqVd472za9m6okK3lxTkV6UyVCq_Kw123NuXorT7_6FcLJb9j0-Zfnjt</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Ammann, Nadine L.</creator><creator>Geidel, Glenn</creator><creator>Schneider, Stefan W.</creator><creator>Gebhardt, Christoffer</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>202109</creationdate><title>Adjuvant pembrolizumab‐related hyperprogression in stage III melanoma</title><author>Ammann, Nadine L. ; Geidel, Glenn ; Schneider, Stefan W. ; Gebhardt, Christoffer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3255-cb891aad01e03a0a22b0d7d1bc88ce71dcb8125869abac3aab730c99aa867d0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Immunotherapy</topic><topic>Melanoma</topic><topic>Monoclonal antibodies</topic><topic>Pembrolizumab</topic><topic>Targeted cancer therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ammann, Nadine L.</creatorcontrib><creatorcontrib>Geidel, Glenn</creatorcontrib><creatorcontrib>Schneider, Stefan W.</creatorcontrib><creatorcontrib>Gebhardt, Christoffer</creatorcontrib><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal der Deutschen Dermatologischen Gesellschaft</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ammann, Nadine L.</au><au>Geidel, Glenn</au><au>Schneider, Stefan W.</au><au>Gebhardt, Christoffer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adjuvant pembrolizumab‐related hyperprogression in stage III melanoma</atitle><jtitle>Journal der Deutschen Dermatologischen Gesellschaft</jtitle><date>2021-09</date><risdate>2021</risdate><volume>19</volume><issue>9</issue><spage>1341</spage><epage>1345</epage><pages>1341-1345</pages><issn>1610-0379</issn><eissn>1610-0387</eissn><cop>Berlin</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/ddg.14535</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1610-0379
ispartof Journal der Deutschen Dermatologischen Gesellschaft, 2021-09, Vol.19 (9), p.1341-1345
issn 1610-0379
1610-0387
language eng
recordid cdi_proquest_miscellaneous_2551210221
source Wiley Online Library - AutoHoldings Journals
subjects Immunotherapy
Melanoma
Monoclonal antibodies
Pembrolizumab
Targeted cancer therapy
title Adjuvant pembrolizumab‐related hyperprogression in stage III melanoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T16%3A38%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adjuvant%20pembrolizumab%E2%80%90related%20hyperprogression%20in%20stage%20III%20melanoma&rft.jtitle=Journal%20der%20Deutschen%20Dermatologischen%20Gesellschaft&rft.au=Ammann,%20Nadine%20L.&rft.date=2021-09&rft.volume=19&rft.issue=9&rft.spage=1341&rft.epage=1345&rft.pages=1341-1345&rft.issn=1610-0379&rft.eissn=1610-0387&rft_id=info:doi/10.1111/ddg.14535&rft_dat=%3Cproquest_cross%3E2551210221%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2579987489&rft_id=info:pmid/&rfr_iscdi=true